Merck & Co is buying Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on glioblastoma (GBM). This could “change the whole landscape,” said Ranjit Bindra, M.D., Ph.D., Modifi co-founder and physician-scientist at the Yale School of Medicine. GBM is the most common type of brain cancer and is a devastating disease,…
Category: Brain tumours
Potential treatments for secondary brain cancer
Drugs already licensed could be trialled to potentially treat secondary brain cancer, new research finds The largest review of papers for brain cancer that has spread from the lungs has found abnormalities in the brain cancer. Licensed drugs could be clinically trialled to find out if they could treat the disease. The research led by…
Powerful AI algorithm to gain new insights into deadly glioblastoma
Scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, US collaborating with international researchers, have developed a sophisticated AI algorithm that performs advanced computational analysis to identify potential therapeutic targets for glioblastoma multiforme (GBM) and other cancers. Their research is described in the Feb. 2 issue of the journal…
